Table 1.
Clinicopathological characteristics of breast cancer patients in the study cohort
| Breast cancer (n = 266) | IDC (n = 180) | |
|---|---|---|
| Surgical treatment | ||
| Lumpectomy | 168 (63.1%) | 113 (62.8%) |
| Mastectomy | 84 (31.6%) | 59 (32.8%) |
| Unknown | 14 (5.3%) | 8 (4.4%) |
| Age at diagnosis (years) | ||
| Median (Range - 30.6–89.8) | 59.2 | 59.2 |
| < 59 | 126 (47.4%) | 88 (48.9%) |
| ≥ 59 | 140 (52.6) | 92 (51.1%) |
| Adjuvant treatment | ||
| Hormonal treatment | ||
| Tamoxifen | 131 (49.2%) | 94 (52.2%) |
| Aromatase Inhibitor | 13 (4.9%) | 8 (4.4%) |
| Chemotherapy | 73 (2.7%) | 66 (24.8%) |
| Radiotherapy | 149 (56.0%) | 101 (56.1%) |
| Therapy details not available | 6 (2.2%) | 6 (3.3%) |
| Tumor size (cm) | ||
| Mean ± SD | 1.85 ± 1.525 | 1.82 ± 1.466 |
| Minimum | 0.1 | 0.1 |
| Maximum | 9 | 9 |
| ≤2 cm | 198 | 81 |
| >2 cm | 57 | 96 |
| Unknown | 11 | 3 |
| AJCC pTNM stage (n, %) | ||
| 0 (DCIS + LCIS) | 62 (23.3%) | - |
| I | 94 (35.3%) | 113(62.8%) |
| II | 87 (32.7%) | 58 (32.2%) |
| III | 6 (2.3%) | 5 (2.8%) |
| IV | 17 (6.4%) | 4 (2.2%) |
| Estrogen receptor (ER) | ||
| Negative | 35 (13.1%) | 33 (18.3%) |
| Positive | 161 (60.6%) | 136 (75.6%) |
| Unknown | 70 (26.3%) | 11 (6.1%) |
| Progesterone receptor (PR) | ||
| Negative | 71(26.7%) | 64 (35.6%) |
| Positive | 123 (46.2%) | 103 (57.2%) |
| Unknown | 72 (27.1%) | 13 (7.2%) |
| Grade | ||
| I | 56 (21.1%) | 42 (23.3%) |
| II | 106 (39.8%) | 66 (36.7%) |
| III | 85 (32.0%) | 65 (36.1%) |
| Unknown | 19 (7.1%) | 7 (3.9%) |
| Nodal status | ||
| Negative | 204 (76.7%) | 123 (68.3%) |
| Positive | 62 (23.3%) | 57 (31.7%) |